Zydus receives approval from USFDA for Mirabegron Extended-Release Tablets
Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and frequency
Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and frequency
Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.
Mirabegron Extended-Release Tablets, 25 mg and 50 mg, had estimated annual sales of US $2.4 billion in US
Sildenafil for Oral Suspension (RLD Revatio) had estimated annual sales of US $64 million in the US
Transformation to pure-play Innovative Medicines company nears completion
The companies will leverage their respective proprietary technology platforms
Diclofenac Sodium Topical Solution USP, 2% w/w (RLD Pennsaid) had estimated annual sales of US $484 million in the US
Sitagliptin is an active ingredient in JANUVIA, JANUMET and JANUMET XR
The ANDA was filed as 'First to File' submission on NCE-1 date.
Subscribe To Our Newsletter & Stay Updated